Wednesday, February 21, 2018
 
 
Company News: Page (1) of 1 - 09/28/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FDA Grants Priority Review for Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer

(September 28, 2017)
[ServletException in:/common/layout/us_view_template.jsp] null'